Mallinckrodt, a provider of specialty pharmaceuticals, plans to invest $2 million to establish its U.S. headquarters in Hazelwood, Missouri, creating 150 jobs.
The firm’s spinoff from former parent company, Covidien, makes it one of the largest public companies in St. Louis. The company is incorporated in Ireland and began officially trading on the New York Stock Exchange. Mallinckrodt's Hazelwood headquarters also serves as its U.S. headquarters. Mallinckrodt currently employs approximately 2,500 workers in the St. Louis area, and has more than 5,500 employees globally.
"As an active member of the St. Louis community for more than 145 years, we will continue to deliver the quality, integrity and service that the Mallinckrodt name is known for, and to help drive economic growth here in Missouri," said Mark Trudeau, President and CEO of Mallinckrodt. "We thank Gov. Nixon and the state of Missouri for their support, and appreciate Acting Department of Economic Development Director Mike Downing's participation in the celebration of our historic launch."
"Missouri companies are leading the way in the health science industry," Gov. Jay Nixon said. "Mallinckrodt's decision to establish the Hazelwood facility as its U.S. headquarters solidifies Missouri's place at the top of the health science industry and keeps our economy moving forward. It's certainly cause for celebration."